# Study of Olutasidenib and Temozolomide in HGG

Source: https://onco.cc/trials/nct06161974/  
OnCo record `nct06161974` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Olutasidenib in diffuse midline glioma, h3 k27-altered, run by Rigel Pharmaceuticals, now recruiting.

## Summary

Study of Olutasidenib and Temozolomide in HGG is a phase 2 interventional study registered as NCT06161974 by Rigel Pharmaceuticals, with 60 participants planned, started 2025-02-01 and due to reach its primary completion in 2029-06. Interventions recorded: Olutasidenib + TMZ. Conditions listed: High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06161974
- Phase: 2
- Setting: Phase 2 Study of Olutasidenib With Temozolomide as Maintenance Therapy in Pediatric and Young Adult Patients Newly Diagnosed With High-Grade Glioma (HGG), Including Diffuse Intrinsic Pontine Glioma (DIPG), Which Harbor IDH1 Mutations
- Sponsor: Rigel Pharmaceuticals
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06161974: https://clinicaltrials.gov/study/NCT06161974

## Connected records

- cancers: [Diffuse midline glioma, H3 K27-altered (including DIPG)](https://onco.cc/cancers/dipg-dmg/)
- drugs: [Olutasidenib](https://onco.cc/drugs/olutasidenib/)
- companies: [Rigel Pharmaceuticals](https://onco.cc/companies/rigel-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06161974.json